Suppr超能文献

代谢型谷氨酸受体增强小鼠皮质楔形标本中NMDA反应的药理学特征

Pharmacological characterization of metabotropic glutamate receptors potentiating NMDA responses in mouse cortical wedge preparations.

作者信息

Mannaioni G, Carlà V, Moroni F

机构信息

Dipartimento di Farmacologia, Preclinica e Clinica, Università di Firenze, Italy.

出版信息

Br J Pharmacol. 1996 Jul;118(6):1530-6. doi: 10.1111/j.1476-5381.1996.tb15570.x.

Abstract
  1. Mouse cortical wedge preparations were used in order to study the effects of metabotropic glutamate receptor (mGluR) agonists and antagonists on the depolarization induced by N-methyl-D-aspartate (NMDA) or by (S)-alpha-amino-4-bromo-3-hydroxy-5-isoxazolepropionic acid (AMPA). 2. (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) (30-300 microM) significantly potentiated the depolarizations induced by NMDA, leaving unchanged those mediated by AMPA. This potentiation developed slowly and lasted for up to 60 min provided that the slices were continuously perfused with the mGluR agonist. 3. Concentration-response curves to NMDA in the absence and in the presence of 1S,3R-ACPD (100 microM) indicated that the potentiation was due to increased affinity of the NMDA receptor complex for its agonist. The maximal responses to NMDA were not potentiated. 4. Selective agonists of group 1 mGluR such as quisqualate (Quis) (30 microM) or (RS)-3,5-dihydroxyphenylglycine (DHPG) (300 microM) did not potentiate NMDA responses. Similarly, selective agonists of group 2 mGluRs, such as (2S,3S,4S)-alpha-carboxycyclopropyl-glycine (L-CCG-I) (3-30 microM), and of group 3, such as L-2-amino-4-phosphonobutyric acid (L-AP4) (100 microM) were inactive in our test. A number of other putative mGluR agents having partial agonist activity on mGluRs in brain slices and in expression systems, such as 1R,3S-ACPD (500 microM), DL-2-amino-3-phosphonopropionic acid (DL-AP3) (300 microM) and (S)-4-carboxy-3-hydroxyphenylglycine (S-4C3HPG; 500 microM), when placed in the experimental protocol we used, did not change NMDA responses. 5. Available mGluR antagonists, such as DL-AP3 (1 mM), (+)-alpha-methyl-4-carboxyphenylglycine (MCPG) (500 microM), S-4-carboxyphenylglycine (4CPG; 500 microM) and S-4-carboxy-3-hydroxyphenylglycine (S-4C3HPG; 500 microM), did not reduce 1S,3R-ACPD potentiation of NMDA responses. 6. It is concluded that the potentiation of NMDA currents induced by the mGluR agonist 1S,3R-ACPD, in mouse cortical wedges, has a pharmacological profile which is different from that of the three mGluR groups so far described in expression systems.
摘要
  1. 为了研究代谢型谷氨酸受体(mGluR)激动剂和拮抗剂对N-甲基-D-天冬氨酸(NMDA)或(S)-α-氨基-4-溴-3-羟基-5-异恶唑丙酸(AMPA)诱导的去极化的影响,使用了小鼠皮质楔形标本。2. (1S,3R)-1-氨基环戊烷-1,3-二羧酸(1S,3R-ACPD)(30 - 300微摩尔)显著增强了NMDA诱导的去极化,而对AMPA介导的去极化没有影响。这种增强作用发展缓慢,只要切片持续用mGluR激动剂灌注,可持续长达60分钟。3. 在不存在和存在1S,3R-ACPD(100微摩尔)的情况下,对NMDA的浓度-反应曲线表明这种增强是由于NMDA受体复合物对其激动剂的亲和力增加。对NMDA的最大反应没有增强。4. 第1组mGluR的选择性激动剂,如喹啉酸(Quis)(30微摩尔)或(RS)-3,5-二羟基苯甘氨酸(DHPG)(300微摩尔),没有增强NMDA反应。同样,第2组mGluR的选择性激动剂,如(2S,3S,4S)-α-羧基环丙基甘氨酸(L-CCG-I)(3 - 30微摩尔)和第3组的选择性激动剂,如L-2-氨基-4-膦酰丁酸(L-AP4)(100微摩尔),在我们的实验中没有活性。许多其他在脑片和表达系统中对mGluR具有部分激动剂活性的假定mGluR剂,如1R,3S-ACPD(500微摩尔)、DL-2-氨基-3-膦酰丙酸(DL-AP3)(300微摩尔)和(S)-4-羧基-3-羟基苯甘氨酸(S-4C3HPG;500微摩尔),在我们使用的实验方案中,没有改变NMDA反应。5. 现有的mGluR拮抗剂,如DL-AP3(1毫摩尔)、(+)-α-甲基-4-羧基苯甘氨酸(MCPG)(500微摩尔)、S-4-羧基苯甘氨酸(4CPG;500微摩尔)和S-4-羧基-3-羟基苯甘氨酸(S-4C3HPG;500微摩尔),没有降低1S,3R-ACPD对NMDA反应的增强作用。6. 得出的结论是,mGluR激动剂1S,3R-ACPD在小鼠皮质楔形标本中诱导的NMDA电流增强,其药理学特征与迄今为止在表达系统中描述的三个mGluR组不同。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验